Status:

COMPLETED

Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis

Lead Sponsor:

GlaxoSmithKline

Conditions:

Viral Hepatitis Vaccines

Hepatitis A

Eligibility:

All Genders

1-70 years

Brief Summary

The purpose of this study is to determine the seroprevalence of Hepatitis A Virus (HAV), Varicella-Zoster virus (VZV), Cytomegalovirus (CMV), Herpes Simplex (HSV) and Bordetella pertussis (BP)infectio...

Detailed Description

In order to document the epidemiological changes in the sero-prevalence of Hepatitis A, Human simplex virus (1 and 2), Varicella-Zoster virus and Cytomegalovirus infections, we propose to conduct a po...

Eligibility Criteria

Inclusion

  • • Previously enrolled subjects aged \>= 1 to 70 years for National Health and Nutrition Survey 2006 in Mexico, with previously obtained informed consent

Exclusion

  • Information required for the study is not available or incomplete.
  • Inadequate or insufficient serum sample to detect viral agents required for the study.
  • Serum sample wrongly identified.

Key Trial Info

Start Date :

March 1 2010

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 1 2010

Estimated Enrollment :

3658 Patients enrolled

Trial Details

Trial ID

NCT01160081

Start Date

March 1 2010

End Date

September 1 2010

Last Update

January 25 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

GSK Investigational Site

Cuernavaca, Morelos, Mexico

Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis | DecenTrialz